{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:20:45Z","timestamp":1792614045340,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:p>Current treatment for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID) includes enzyme replacement therapy (ERT), allogeneic hematopoietic stem cell transplant (HSCT), or ex vivo corrected autologous hematopoietic stem cell gene therapy. Historic data show HSCT survival is superior using unconditioned matched sibling and family compared to matched unrelated and haploidentical donors. Recent improvement in HSCT outcomes prompted us to retrospectively examine HSCT survival and long-term graft function in ADA-SCID transplanted at our center. Thirty-three ADA-deficient patients received HSCT between 1989 and 2020, with follow-up data to January 2021. Chemotherapy conditioning regimens were defined as myeloablative (MAC\u2014busulfan\/cyclophosphamide), reduced-toxicity myeloablative (RT-MAC\u2014treosulfan-based, since 2007), or no conditioning. Serotherapy used included alemtuzumab (with or without other conditioning agents) or antithymocyte globulin (ATG). ERT was introduced routinely in 2010 until commencement of conditioning. Median age at HSCT was 3.2 (0.8\u201399.8) months. Twenty-one (63.6%) received stem cells from unrelated or haploidentical donors. Seventeen (51.5%) received chemotherapy conditioning and 16 (48.5%) received alemtuzumab. Median follow-up was 7.5 (0.8\u201325.0) years. Overall survival (OS) and event-free survival (EFS) at 8\u00a0years were 90.9% (95% CI: 79.7\u2013100.0%) and 79% (55\u201391%), respectively. OS after 2007 (<jats:italic>n<\/jats:italic>\u2009=\u200921) was 100% vs 75% before 2007 (<jats:italic>n<\/jats:italic>\u2009=\u200912) (<jats:italic>p<\/jats:italic>\u2009=\u20090.02). Three (9.1%) died after HSCT: two from multiorgan failure and one from unexplained encephalopathy. There were no deaths after 2007, among those who received ERT and treosulfan-based conditioning pre-HSCT. Ten (30.3%) developed acute GvDH (3 grade II, 2 grade III); no chronic GvHD was observed. In the modern era, conditioned HSCT with MUD has a favorable outcome for ADA-deficient patients.<\/jats:p>","DOI":"10.1007\/s10875-022-01238-0","type":"journal-article","created":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T04:41:10Z","timestamp":1647319270000},"page":"819-826","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Hematopoietic Cell Transplantation for Adenosine Deaminase Severe Combined Immunodeficiency\u2014Improved Outcomes in the Modern Era"],"prefix":"10.1007","volume":"42","author":[{"given":"Elisabetta","family":"Ghimenton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisling","family":"Flinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Han","family":"Lum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Leahy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohreh","family":"Nademi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleri","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terrence","family":"Flood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Hambleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Slatter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6218-1324","authenticated-orcid":false,"given":"Andrew R.","family":"Gennery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,15]]},"reference":[{"issue":"7","key":"1238_CR1","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s10875-017-0433-3","volume":"37","author":"KL Bradford","year":"2017","unstructured":"Bradford KL, Moretti FA, Carbonaro-Sarracino DA, Gaspar HB, Kohn DB. Adenosine deaminase (ADA)-deficient severe combined immune deficiency (SCID): molecular pathogenesis and clinical manifestations. J Clin Immunol. 2017;37(7):626\u201337.","journal-title":"J Clin Immunol"},{"issue":"2","key":"1238_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.iac.2010.01.002","volume":"30","author":"HB Gaspar","year":"2010","unstructured":"Gaspar HB. Bone marrow transplantation and alternatives for adenosine deaminase deficiency. Immunol Allergy Clin North Am. 2010;30(2):221\u201336.","journal-title":"Immunol Allergy Clin North Am"},{"issue":"8","key":"1238_CR3","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1007\/s10875-021-01106-3","volume":"41","author":"H Burns","year":"2021","unstructured":"Burns H, Collins A, Marsden P, Flood TJ, Slatter MA, Booth C, et al. Severe combined immunodeficiency (SCID)-the Irish experience. J Clin Immunol. 2021;41(8):1950\u20133.","journal-title":"J Clin Immunol"},{"issue":"1","key":"1238_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13023-018-0807-5","volume":"13","author":"AM Flinn","year":"2018","unstructured":"Flinn AM, Gennery AR. Adenosine deaminase deficiency: a review. Orphanet J Rare Dis. 2018;13(1):65.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"1238_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.clim.2005.07.006","volume":"117","author":"B Chan","year":"2005","unstructured":"Chan B, Wara D, Bastian J, Hershfield MS, Bohnsack J, Azen CG, et al. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). Clin Immunol. 2005;117(2):133\u201343.","journal-title":"Clin Immunol"},{"key":"1238_CR6","doi-asserted-by":"crossref","unstructured":"Hassan A, Booth C, Brightwell A, Allwood Z, Veys P, Rao K, et al. Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency. Blood. 2012;120(17):3615\u201324; quiz 26.","DOI":"10.1182\/blood-2011-12-396879"},{"issue":"8","key":"1238_CR7","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1007\/s10875-020-00857-9","volume":"40","author":"CY Kuo","year":"2020","unstructured":"Kuo CY, Garabedian E, Puck J, Cowan MJ, Sullivan KE, Buckley RH, et al. Adenosine deaminase (ADA)-deficient severe combined immune deficiency (SCID) in the US Immunodeficiency Network (USIDNet) Registry. J Clin Immunol. 2020;40(8):1124\u201331.","journal-title":"J Clin Immunol"},{"issue":"1","key":"1238_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood-2016-01-688226","volume":"128","author":"MP Cicalese","year":"2016","unstructured":"Cicalese MP, Ferrua F, Castagnaro L, Pajno R, Barzaghi F, Giannelli S, et al. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency. Blood. 2016;128(1):45\u201354.","journal-title":"Blood"},{"issue":"3","key":"1238_CR9","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.jaci.2018.08.024","volume":"143","author":"DB Kohn","year":"2019","unstructured":"Kohn DB, Hershfield MS, Puck JM, Aiuti A, Blincoe A, Gaspar HB, et al. Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency. J Allergy Clin Immunol. 2019;143(3):852\u201363.","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"1238_CR10","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1038\/s41409-021-01378-8","volume":"56","author":"AC Lankester","year":"2021","unstructured":"Lankester AC, Albert MH, Booth C, Gennery AR, G\u00fcng\u00f6r T, H\u00f6nig M, et al. EBMT\/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity. Bone Marrow Transplant. 2021;56(9):2052\u201362.","journal-title":"Bone Marrow Transplant"},{"issue":"21","key":"1238_CR11","first-page":"01629","volume":"S0091\u20136749","author":"AC Lankester","year":"2021","unstructured":"Lankester AC, Neven B, Mahlaoui N, von Asmuth EGJ, Courteille V, Alligon M, et al. (2021) Advances in hematopoietic stem cell transplantation in severe combined immunodeficiency: a report on the SCETIDE 2006\u20132014 European cohort. J Allergy Clin Immunol. 2021;S0091\u20136749(21):01629\u20138.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1238_CR12","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s10875-021-01145-w","volume":"42","author":"AY Kreins","year":"2022","unstructured":"Kreins AY, Velasco HF, Cheong KN, Rao K, Veys P, Worth A, et al. Long-term immune recovery after hematopoietic stem cell transplantation for ADA deficiency: a single-center experience. J Clin Immunol. 2022;42(1):94\u2013107.","journal-title":"J Clin Immunol"},{"issue":"6","key":"1238_CR13","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.jaci.2012.02.003","volume":"129","author":"E Grunebaum","year":"2012","unstructured":"Grunebaum E, Cutz E, Roifman CM. Pulmonary alveolar proteinosis in patients with adenosine deaminase deficiency. J Allergy Clin Immunol. 2012;129(6):1588\u201393.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1238_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s10875-017-0373-y","volume":"37","author":"DB Kohn","year":"2017","unstructured":"Kohn DB, Gaspar HB. How we manage adenosine deaminase-deficient severe combined immune deficiency (ADA SCID). J Clin Immunol. 2017;37(4):351\u20136.","journal-title":"J Clin Immunol"},{"issue":"2","key":"1238_CR15","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jaci.2020.04.053","volume":"146","author":"SH Lum","year":"2020","unstructured":"Lum SH, Selvarajah S, Deya-Martinez A, McNaughton P, Sobh A, Waugh S, et al. Outcome of autoimmune cytopenia after hematopoietic cell transplantation in primary immunodeficiency. J Allergy Clin Immunol. 2020;146(2):406\u201316.","journal-title":"J Allergy Clin Immunol"},{"issue":"21","key":"1238_CR16","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1056\/NEJMoa2027675","volume":"384","author":"DB Kohn","year":"2021","unstructured":"Kohn DB, Booth C, Shaw KL, Xu-Bayford J, Garabedian E, Trevisan V, et al. Autologous ex vivo lentiviral gene therapy for adenosine deaminase deficiency. N Engl J Med. 2021;384(21):2002\u201313.","journal-title":"N Engl J Med"},{"issue":"3","key":"1238_CR17","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.ymthe.2017.12.022","volume":"26","author":"MP Cicalese","year":"2018","unstructured":"Cicalese MP, Ferrua F, Castagnaro L, Rolfe K, De Boever E, Reinhardt RR, et al. Gene therapy for adenosine deaminase deficiency: a comprehensive evaluation of short- and medium-term safety. Mol Ther. 2018;26(3):917\u201331.","journal-title":"Mol Ther"},{"key":"1238_CR18","unstructured":"30 October 2020 [Available from: https:\/\/ir.orchard-tx.com\/index.php\/news-releases\/news-release-details\/orchard-statement-strimvelisr-gammaretroviral-vector-based-gene.\u00a0Accessed 04\/03\/2022."},{"key":"1238_CR19","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1182\/blood.2020010260","volume":"138","author":"B Reinhardt","year":"2021","unstructured":"Reinhardt B, Habib O, Shaw KL, Garabedian E, Carbonaro-Sarracino DA, Terrazas D, et al. Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency. Blood. 2021;138:1304\u201316.","journal-title":"Blood"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-022-01238-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-022-01238-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-022-01238-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T16:12:24Z","timestamp":1654272744000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-022-01238-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,15]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1238"],"URL":"https:\/\/doi.org\/10.1007\/s10875-022-01238-0","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,15]]},"assertion":[{"value":"29 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The families gave fully informed consent to treatment and data collection according to institutional protocols.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Freely given written informed consent was obtained from participants\/parents or legal guardians for publication as per institutional practice.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}